The latest price target for Lisata Therapeutics (NASDAQ:LSTA) was reported by HC Wainwright & Co. on May 15, 2026. The analyst firm set a price target for $0.00 expecting LSTA to fall to within 12 months (a possible -100.00% downside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for Lisata Therapeutics (NASDAQ:LSTA) was provided by HC Wainwright & Co., and Lisata Therapeutics downgraded their neutral rating.

There is no last upgrade for Lisata Therapeutics

The last downgrade for Lisata Therapeutics Inc happened on May 15, 2026 when HC Wainwright & Co. changed their price target from N/A to N/A for Lisata Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lisata Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lisata Therapeutics was filed on May 15, 2026 so you should expect the next rating to be made available sometime around May 15, 2027.

While ratings are subjective and will change, the latest Lisata Therapeutics (LSTA) rating was a downgraded with a price target of $0.00 to $0.00. The current price Lisata Therapeutics (LSTA) is trading at is $3.19, which is out of the analyst’s predicted range.